Complex autologous cellular product

The term Complex autologous cellular product refers to a therapeutic modality rather than a specific molecular target like a receptor or enzyme. This classification is used by regulatory bodies such as the FDA and EMA to describe treatments where a patient's own biological cells are harvested, modified outside the body, and re-administered to treat diseases (FDA, 2023). Common examples include Chimeric Antigen Receptor (CAR) T-cell therapies and autologous stem cell transplants, which are primarily used in the treatment of refractory hematologic malignancies and certain solid tumors (June et al., 2018; EMA, 2022). These products function as living drugs, capable of expanding within the patient and providing long-term surveillance or tissue regeneration. Because the therapy is derived from the patient's own cells, it minimizes the risk of graft-versus-host disease but introduces significant complexity in manufacturing and quality control. Clinical monitoring often focuses on systemic inflammatory responses, such as cytokine release syndrome, which can result from the rapid activation of these cellular products (StatPearls, 2023). Consequently, this entry serves as a placeholder in pharmacological databases for therapies that lack a discrete, single-molecule target.

Other names

Autologous cell therapyPatient-derived cellular productAutologous cellular immunotherapyAdvanced therapy medicinal product (ATMP)Autologous cell-based gene therapy

The mechanism of action involves the collection of a patient's own cells, which are then processed, expanded, or genetically modified (e.g., via viral vectors to express Chimeric Antigen Receptors) ex vivo before being re-infused into the patient to exert a therapeutic effect, such as targeted tumor cell lysis or functional protein production (FDA, 2023; June et al., 2018).